Медицинская библиотека · Breast (Edinburgh, Scotland) · 2026

De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.

Sella Tal, van Duijnhoven Frederieke, Wildiers Hans, Venieri Claudio, Pogoda Katarzyna, Linderholm Barbro, Matos Leonor, Shirron Natali, De Maio D'Esposito Eleonora, Hajjaji Nawale, Matos Erika, González Cortijo Lucía, Lambertini Matteo, Fortuna Ana, Rosset Laurent, Constantinidou Anastasia, Demasure Sofie, Abu Remilah Areen, Huygh Greet, Paluch-Shimon Shani, Tjan-Heijnen Vivianne, Ruyssers Natacha, Gouveia Helena, Angeli Eurydice, Cicin Irfan, Chiappe Edoardo, Neven Patrick, Artac Mehmet, Kilictas Bilgesah, Baranseh Jalal, Vicente-Rubio Elena, Atci Mustafa, Shai Ayelet

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Use of taxane-only chemotherapy for stage I HR+/HER2+ breast cancer has increased, potentially preserving ovarian function and shifting endocrine therapy (ET) strategies. Outcomes in premenopausal women were not defined.

METHODS

Patients ≤45 years with stage I HR+/HER2+ breast cancer were identified from a multicenter registry. IDFS was assessed by chemotherapy and ET.

RESULTS

Thirteen IDFS events (4 distant) occurred among 244 patients. Six-year IDFS was 95.5% (multiagent chemotherapy) and 94.1% (taxane-only) (p = 0.56), and 95.9%, 93.8%, and 96.9% with tamoxifen, tamoxifen + OFS, and AI + OFS (p = 0.56).

CONCLUSIONS

Outcomes were excellent regardless of chemotherapy or ET, suggesting limited incremental benefit from treatment intensification.

Для цитирования: Sella Tal, van Duijnhoven Frederieke, Wildiers Hans, Venieri Claudio, Pogoda Katarzyna, Linderholm Barbro, Matos Leonor, Shirron Natali, De Maio D'Esposito Eleonora, Hajjaji Nawale, Matos Erika, González Cortijo Lucía, Lambertini Matteo, Fortuna Ana, Rosset Laurent, Constantinidou Anastasia, Demasure Sofie, Abu Remilah Areen, Huygh Greet, Paluch-Shimon Shani, Tjan-Heijnen Vivianne, Ruyssers Natacha, Gouveia Helena, Angeli Eurydice, Cicin Irfan, Chiappe Edoardo, Neven Patrick, Artac Mehmet, Kilictas Bilgesah, Baranseh Jalal, Vicente-Rubio Elena, Atci Mustafa, Shai Ayelet. De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.. Breast (Edinburgh, Scotland). 2026. DOI: 10.1016/j.breast.2026.104838.

Предметные рубрики MeSH

Adult Female Humans Antineoplastic Agents, Hormonal Antineoplastic Combined Chemotherapy Protocols Aromatase Inhibitors Breast Neoplasms Chemotherapy, Adjuvant Disease-Free Survival Erb-b2 Receptor Tyrosine Kinases Neoplasm Staging Premenopause Receptors, Estrogen Receptors, Progesterone Registries Tamoxifen Taxoids Treatment Outcome

Подготовка и перевод публикации

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.